Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
It is well known that thyroid hormones modulate lipoprotein metabolism. Thus, the presence of clinical or subclinical hyperthyroidism may influence lipid parameters of dyslipidaemic patients and the efficacy of hypolipidaemic therapy. Here we present a patient with mixed hyperlipidaemia whose impressive improvement of his lipid profile following ciprofibrate administration pointed towards the diagnosis of asymptomatic underlying subclinical hyperthyroidism.
Liberopoulos
E
E
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Miltiadous
G
G
Elisaf
M
M
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D006980:Hyperthyroidism / Q000150:complications / Q000175:diagnosis*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D014284:Triiodothyronine; D002995:Clofibric Acid; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin; C019304:ciprofibrate; D013974:Thyroxine